Compass Pathways reported positive 26-week Phase 3 results for COMP360 in treatment-resistant depression, with 39% of the 25mg group achieving sustained clinical response and nearly 30% reaching full remission — outcomes that substantially exceed existing TRD therapies and support a rolling NDA targeting H1 2027 market entry.

Key Highlights

  • 39% Sustained Response at 26 Weeks: The COMP006 Phase 3 trial of 581 patients showed that 39% of the 25mg COMP360 group achieved sustained clinical response through the 26-week assessment — a durability metric that directly addresses the primary regulatory and commercial concern about psychedelic therapy's longevity of benefit.
  • Nearly 30% Full Remission Rate: A two-dose regimen drove nearly 30% of responders into full clinical remission — a substantially higher remission rate than currently approved TRD therapies including esketamine (Spravato), which reports approximately 15-20% remission rates in comparable refractory populations.
  • H1 2027 Market Entry Target: Supported by an FDA Priority Review Voucher and a rolling NDA process, Compass is targeting complete NDA filing in Q4 2026 and anticipated market entry in the first half of 2027 — a timeline that would make COMP360 the first approved synthetic psilocybin therapy for any psychiatric indication.

Treatment-Resistant Depression: The Scale of Unmet Need

Treatment-resistant depression (TRD) is defined as major depressive disorder that has failed to respond adequately to at least two separate antidepressant trials of appropriate dose and duration. Approximately 3-4 million Americans meet this definition, representing a patient population characterised by extreme suffering, high disability rates, frequent hospitalisation, and an elevated suicide risk that standard antidepressant therapies have proven insufficient to mitigate across decades of prescribing.

Existing approved TRD options are limited and imperfect. Esketamine (Spravato), a nasal spray NMDA receptor antagonist, requires in-clinic administration under supervision due to dissociation risk and achieves remission rates of approximately 15-20% in responsive patients. Transcranial magnetic stimulation, electroconvulsive therapy, and various augmentation strategies provide benefit for subsets of TRD patients but carry significant logistical, side effect, or accessibility burdens. The unmet need that drives 3-4 million Americans to seek alternatives to existing therapies makes the TRD market one of the largest commercially addressable opportunities in psychiatry.

The COMP006 Phase 3 Data: What 26 Weeks of Durability Means

The 26-week sustained response data from the COMP006 trial is the most clinically and commercially significant result in the COMP360 programme's history. Early Phase 2 results established that psilocybin could produce rapid antidepressant effects — but the critical regulatory and prescriber question was always whether those effects persisted over a clinically meaningful time horizon without requiring frequent re-dosing. The 39% sustained response rate at 26 weeks directly answers this question: nearly four in ten patients treated with the 25mg COMP360 dose maintained their antidepressant response for six months following a two-dose treatment course.

The near-30% full remission rate within the responder group is particularly compelling. In TRD — a population that has by definition already failed multiple prior treatments — remission rates of this magnitude represent a therapeutic impact that most psychiatrists would regard as genuinely transformative. The clean safety profile with no new safety signals at 26 weeks addresses the primary prescriber concern about psychedelic-assisted therapy in chronic outpatient practice settings and removes what had been a key regulatory risk in the NDA review process.

The Regulatory Pathway and First-Mover Commercial Position

Compass is pursuing a rolling NDA submission strategy — submitting completed sections for FDA review before the full data package is compiled — in combination with a Priority Review Voucher that will reduce the standard FDA review timeline from 12 months to 6 months once the complete submission is filed. The combined effect of rolling submission and priority review creates a regulatory acceleration strategy that maximises the probability of the earliest possible approval decision relative to standard NDA timelines.

First-mover status as the first FDA-approved synthetic psilocybin therapy would provide Compass with durable prescriber brand recognition, payer formulary positioning, and clinical practice guideline advantages that competitors entering the psilocybin space subsequently would need to actively displace. The commercial opportunity across the 3-4 million US TRD patients — at the premium pricing that psychedelic-assisted therapy with required clinical supervision infrastructure would command — makes COMP360's first-mover position strategically invaluable.

 

Disclaimer: This article is for informational and educational purposes only and does not constitute financial or investment advice. Readers should conduct their own due diligence before making investment decisions.